The new machinery, called a "chimeric antigen receptor" or "Car," transforms a diverse T-cell population into Car-T, where the engineered cells all respond to the same cancer-associated marker. Both ...
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys") and SpayVac for Wildlife, Inc. are pleased to ...
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys") and SpayVac for Wildlife, Inc. are pleased to ...
Discover six bispecific antibody companies developing a two-in-one approach to delivering targeted therapeutics to patients.
Johnson & Johnson announced today more than 90 abstracts featuring data from the Company's differentiated blood cancer portfolio and pipeline will be presented at the 66th American Society of ...
We recently compiled a list of the 10 Best German Stocks To Buy Now. In this article, we are going to take a look at where ...
News Medical on MSN20h
New CAR T-cell therapy shows promise against aggressive HER2+ breast cancerOne-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast ...
They may need radiation if the surgeon is unable to remove all the cancer, or if prostate-specific antigen is still ...
Upcoming oral presentation for the ALLOHATM Phase 1 heme trial at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition Company to host virtual KOL event featuring Ran Reshef, M.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback